Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PiggyBac Anti-CD19 CAR-T in R/R B-cell Malignancies
NCT04289220Phase 1Unknown
- Sponsor
- Yan'an Affiliated Hospital of Kunming Medical University
- Start
- Mar 2020
- Primary completion
- Mar 2023
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial in B cell lymphoma, B cell acute lymphoblastic leukemia (B-ALL) and multiple myeloma (MM), sponsored by Yan'an Affiliated Hospital of Kunming Medical University. Primary endpoints: Grade and number of cytokine release syndrome and neurotoxic effects at 14 days and Persistence of anti-CD19 CAR-T cells at 1 year. Status: unknown.
02
Conditions
B cell lymphomaB cell acute lymphoblastic leukemia (B-ALL)multiple myeloma (MM)
Beyond the preview
Go deeper on NCT04289220.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04289220.